8 Best Small-Cap Biotech Stocks — September 2026

Small-cap biotech enters September 2026 with the strongest macro setup the sector has seen in years — and, unusually, the hard numbers back the mood. The Federal Reserve delivered three rate cuts in 2025, and clinical-stage biotech is among the most rate-sensitive corners of the equity market: lower discount rates re-rate cash flows that sit years in the future, and cheaper capital reopens the financing window that funds trials. On top of that sits the acquirer bid. Big Pharma faces a patent cliff by 2030 — Keytruda, Eliquis, Opdivo and Darzalex all lose exclusivity by the end of the decade, with estimates of the revenue at risk ranging from roughly $170 billion to $300 billion — and biopharma M&A had already reached about $106 billion across 201 transactions in 2026 by early June, on track for the best year since before the pandemic.

The small-cap layer is where that dynamic bites hardest, because acquirers are favoring exactly what fundamental screens surface: de-risked, commercial or near-commercial assets rather than preclinical stories. Our screen of 300+ biotech names in the SmallCapScanner universe shows a split market — a cohort of newly profitable commercial companies with real revenue growth and net-cash balance sheets scores dramatically better than the long tail of cash-burning developers. Below: eight names ranked by our August 30 fundamentals snapshot, spanning market caps from $0.22B to $2.2B. The list deliberately mixes profiles — commercial rare-disease and specialty franchises, newly launched oncology assets, and partnered discovery platforms — because score quality means something different in each sub-segment. This complements our evergreen small-cap biotech list with a fresh, snapshot-ranked September view.

---

Why the Small-Cap Biotech Setup Is Different This Cycle

1. Rate cuts re-rate the longest-duration cash flows in the market. Three Federal Reserve cuts in 2025 did two things at once: they lifted the present value of profits that arrive years from now, and they reopened the equity and partnership financing window that determines whether developers negotiate from strength or desperation. Seven of the eight names here are net cash or self-funding and benefit from a reopened window without needing it; only NUVB, with 11 months of scored runway, still needs its launch ramp to deliver.

2. The patent cliff is forcing Big Pharma's hand. With roughly $170-300 billion of branded revenue exposed to expiration by 2030, acquirers are racing to replace it — about $106 billion of biopharma M&A across 201 transactions in 2026 by early June, the strongest pace since before the pandemic. Crucially, buyers favor de-risked, commercial-stage assets over preclinical stories. That is precisely the profile a fundamentals score promotes: real revenue, high gross margins, funded balance sheets.

3. The score separates a split market — if you read it correctly. In biotech, revenue growth is not one thing. CorMedix's +617% blends a launch with an acquisition; Compugen's +161% and Septerna's +4,175% are partnership monetizations, not product sales; Zevra's +351% is the steep part of an orphan-drug launch curve. The score surfaces the balance-sheet strength behind those numbers, but the sub-segment context below tells you which growth rates can compound and which are one-off.

The honest bear case: everything in points one and two is macro, and macro reverses. A hotter inflation print that stalls the cutting cycle would hit long-duration biotech first, and M&A enthusiasm follows the financing cycle it feeds on. Company-specific risk is sharper still — CorMedix's DefenCath economics lean on a temporary reimbursement mechanism, Harmony's franchise faces a patent trial with closing arguments on October 22, 2026, and Septerna has already shown how fast platform stories can reprice, discontinuing its first clinical candidate in early 2025. Milestone-driven revenue spikes normalize; single-product concentration does not diversify itself. Small-cap biotech rewards position sizing discipline more than any sector we cover.

The Names

CRMD — CorMedix Inc.

Score: 90.3 (EXCELLENT) | Market cap: $0.59B | Revenue YoY: +617.0% | Rule of 40: 665.2 | Cash runway: net cash

CorMedix sells DefenCath, the only FDA-approved antimicrobial catheter lock solution for hemodialysis patients, with supply agreements across all five of the largest U.S. dialysis organizations. The roughly $300 million Melinta acquisition (September 2025) added a marketed anti-infectives portfolio and turned a single-product launch into a diversified, profitable acute-care company: Q2 2026 revenue of $101.9 million, $26.0 million net income, $58.7 million adjusted EBITDA. Management guides to $325-345 million in 2026 revenue, including $175-195 million from DefenCath, with adjusted EBITDA guidance raised to $125-140 million. The top score on this list reflects a rare biotech combination: triple-digit growth, high gross margin, net cash. The +617% is a launch-plus-acquisition effect and will normalize; the catalyst is the newest large dialysis organization starting its DefenCath pilot in Q3 2026, the risk a reimbursement reset when CMS's temporary TDAPA add-on payment window closes. → See full CRMD score card

CGEN — Compugen Ltd.

Score: 90.1 (EXCELLENT) | Market cap: $0.22B | Revenue YoY: +161.1% | Rule of 40: 204.2 | Cash runway: net cash

Compugen is a computational drug-discovery platform whose predictive biology has produced two immuno-oncology assets licensed to big pharma: the TIGIT antibody inside AstraZeneca's rilvegostomig, now in 12 ongoing Phase 3 trials, and an anti-IL-18 antibody in Phase 1 with Gilead. In Q4 2025 AstraZeneca paid $65 million for a portion of Compugen's rilvegostomig royalty interest, with a potential additional $25 million on BLA acceptance — that monetization drives the +161% growth and inflated Rule of 40, so treat those metrics as deal-driven rather than recurring sales. Net cash at a $0.22 billion market cap means a large share of the valuation is covered by the balance sheet. The defining catalyst is wholly owned COM701 in the MAIA-ovarian trial, with interim progression-free survival data expected by Q1 2027. The risk: no product revenue of its own — if COM701 disappoints or a partner deprioritizes, the milestone stream dries up quickly. → See full CGEN score card

RIGL — Rigel Pharmaceuticals, Inc.

Score: 87.2 (EXCELLENT) | Market cap: $0.68B | Revenue YoY: +64.1% | Rule of 40: 106.8 | Cash runway: net cash

Rigel is a profitable commercial hematology-oncology company with three marketed products: TAVALISSE for chronic immune thrombocytopenia ($47.4 million in Q2 2026, +18% year over year), REZLIDHIA for relapsed/refractory AML ($8.9 million, +27%) and GAVRETO for RET-altered cancers ($10.7 million). Q2 total revenue reached $78.7 million, and management raised full-year 2026 guidance to $285-295 million. The transformational move is VEPPANU (vepdegestrant), the first FDA-approved PROTAC protein degrader: approved May 1, 2026 for ESR1-mutated breast cancer, in-licensed globally for $85 million, on the market since August 2026 — and not yet in guidance. The score reflects product-driven growth, net cash and 93% gross margins rather than one-off milestones. The risk is competitive: an established oral SERD already holds the ESR1 market, GAVRETO is shrinking, and a stalled VEPPANU launch would weigh on an otherwise profitable base. → See full RIGL score card

ZVRA — Zevra Therapeutics, Inc.

Score: 83.5 (EXCELLENT) | Market cap: $0.56B | Revenue YoY: +350.9% | Rule of 40: 346.9 | Cash runway: 469 months

Zevra is built around MIPLYFFA (arimoclomol), the first FDA-approved treatment for Niemann-Pick disease type C, an ultra-rare and fatal genetic disorder. The launch is executing: Q2 2026 net revenue of $39.7 million (+53% year over year), of which $30.2 million came from MIPLYFFA (+40%), with 184 prescription enrollment forms since launch, payer coverage at 69% of covered lives and high refill and persistence rates. Adjusted net income was positive, and $260.2 million in cash explains the effectively unconstrained runway in the score. The +351% growth captures the steep part of an orphan-drug launch curve — ultra-rare launches tend to keep compounding as diagnosed patients are found and retained, and continued quarter-over-quarter uptake plus geographic expansion are the catalysts. The offset: the addressable population is tiny, so growth flattens once the prevalent diagnosed pool is enrolled, and at roughly 4.6x sales the market is already paying for flawless execution. → See full ZVRA score card

HRMY — Harmony Biosciences Holdings

Score: 80.0 (SOLID) | Market cap: $2.04B | Revenue YoY: +21.5% | Rule of 40: 45.5 | Cash runway: net cash

Harmony is the most established business on this list: WAKIX (pitolisant), its non-scheduled narcolepsy treatment, generated $261.3 million in Q2 2026 net revenue (+30% year over year) in its seventh commercial year, and management guides to over $1 billion in 2026 net revenue. The company is profitable, net cash, and buying growth optionality through a CNS pipeline led by the orexin-2 agonist BP-205, with encouraging initial clinical data alongside Q2 results. The score treats Harmony as a steady compounder — moderate growth, strong margins, clean balance sheet — which is exactly what it is. What the score cannot see: this is a one-drug company whose WAKIX exclusivity runs to March 2030. Harmony has settled with 6 of 7 ANDA filers; the remaining patent trial reaches closing arguments on October 22, 2026 — a binary date. The thesis depends on converting cash and pipeline into a second franchise before the cliff. → See full HRMY score card

AUPH — Aurinia Pharmaceuticals Inc

Score: 76.8 (SOLID) | Market cap: $1.91B | Revenue YoY: +20.4% | Rule of 40: 58.0 | Cash runway: net cash

Aurinia markets LUPKYNIS (voclosporin), the first FDA-approved oral therapy for lupus nephritis, and has quietly become a profit machine: Q2 2026 total revenue of $83.2 million with LUPKYNIS net sales of $79.4 million (+19% year over year), net income of $37.4 million, and reiterated 2026 guidance of $315-325 million. The negative dilution figure behind the score reflects share buybacks — rare capital discipline for a small-cap biotech. A patent settlement with Teva has removed the near-term generic overhang, and the pipeline, led by AUR200 targeting BAFF and APRIL in autoimmune disease, offers a second act. The score reads as a steady, self-funding immunology franchise; the catalyst is continued double-digit LUPKYNIS growth plus pipeline readouts. The risk mirrors Harmony's: competing lupus nephritis regimens, including biologics, fight for the same patients — if growth stalls, the buyback-supported story loses its engine before AUR200 can matter. → See full AUPH score card

NUVB — Nuvation Bio Inc.

Score: 76.2 (SOLID) | Market cap: $2.20B | Revenue YoY: +699.0% | Rule of 40: 360.2 | Cash runway: 11 months

Nuvation Bio is a newly commercial oncology company: IBTROZI (taletrectinib), its ROS1 inhibitor for ROS1-positive non-small cell lung cancer, was FDA-approved in June 2025 and is already the most-prescribed ROS1 TKI for new patient starts in 2026 per IQVIA claims data. Q2 2026 total revenue was $31.7 million, including $23.2 million of IBTROZI net product revenue (+25% quarter over quarter), with roughly 160 new patient starts — about 85% of them TKI-naive, the front-line setting where patients stay on therapy longest. The +699% growth is the arithmetic of a first full launch year, and the 11-month runway is computed from trailing launch-phase burn; it understates the real position as product revenue scales toward covering costs. The catalyst is sequential IBTROZI growth toward break-even. The risks are concentration: ROS1-positive NSCLC is a 1-2% niche, IBTROZI competes head-on with repotrectinib, and roughly 15x sales assumes the launch keeps winning. → See full NUVB score card

SEPN — Septerna, Inc.

Score: 67.5 (SOLID) | Market cap: $1.55B | Revenue YoY: +4174.5% | Rule of 40: 3998.7 | Cash runway: net cash

Septerna is the clinical-stage platform bet on this list: its Native Complex Platform industrializes drug discovery against G protein-coupled receptors, one of the hardest target classes for oral small molecules. The validation came in May 2025: Novo Nordisk signed an exclusive global collaboration for oral small molecules in obesity and cardiometabolic disease — four programs against GPCR targets including the GLP-1, GIP and glucagon receptors, worth up to roughly $2.2 billion including more than $200 million in upfront and near-term payments. That deal is the entire explanation for the +4,175% growth and absurd Rule of 40: partnership payments, not product sales — balance-sheet fuel, not a business trend. The risk is binary: Septerna already discontinued its first clinical candidate in early 2025, and at a $1.55 billion market cap a setback in the Novo programs removes most of the case in one headline. → See full SEPN score card

---

How to Think About Position Sizing

Eight names, three structurally different trades. The profitable franchises — CRMD, RIGL, ZVRA, HRMY, AUPH — sell approved products into defined markets and fund themselves; they are the core, and their risks are specific and monitorable: a reimbursement window (CRMD), a patent docket (HRMY), single-product concentration (AUPH, ZVRA). The launch ramp — NUVB — sits in the middle: real product revenue growing fast, but the cash position still needs the ramp to keep delivering, so it deserves a growth-sleeve weighting, not a core one. The platform options — CGEN and SEPN — are net-cash lottery tickets, but the floors differ: CGEN's balance sheet covers a large share of its $0.22 billion valuation, while SEPN's $1.55 billion price rests almost entirely on its platform and the Novo partnership. In both, the upside depends on partners and binary readouts, so size them as the options they are.

What the mix does not diversify: the sector's discount-rate sensitivity. All eight re-rate together if the Fed's cutting cycle stalls, and the two platform names would feel it most. The offsetting comfort is the acquirer bid — the patent-cliff math that pulls Big Pharma toward exactly these de-risked, commercial-stage profiles does not care about any single quarter.

How We Scored

Our model rates every US small-cap stock across eight fundamentals: revenue growth, gross margin, cash runway, debt/equity, P/S ratio, Rule of 40, insider ownership, and 12-month dilution. Sector-adjusted where appropriate, refreshed regularly — this list uses the August 30 snapshot. See methodology and track record or browse all small-cap Healthcare stocks.

Related Coverage

• 7 Best Small-Cap Biotech Stocks for 2026 (Cash + Pipeline)
• 6 Best Small-Cap Gold Stocks — September 2026
• 7 Best Small-Cap Nuclear & SMR Stocks — September 2026
• 7 Best Small-Cap Data Center Infrastructure Stocks — June 2026

Data as of August 30, 2026. Updated monthly. Past performance does not guarantee future results. Not investment advice.